Scientists at Helmholtz Zentrum für Infektionsforschung GmbH and Medizinische Hochschule Hannover have divulged oxadiazole derivatives reported to be useful for the treatment of cytomegalovirus infections.
In the search for more potent, safe and effective autophagy inhibitor compounds, researchers from the Wayne State University School of Medicine have developed novel piperazine- and piperidine-substituted quinoline derivatives GL-287 and GL-382, based on the quinoline scaffold of hydroxychloroquine.
Transient receptor potential canonical (TRPC) channels are known to play a key role in regulating nervous system excitability and they have been previously implicated in seizure development.
Antimicrobial peptides, existing in animals and plants, are the first line of defense of the organisms against bacteria. Thymol and carvacrol are two monoterpenoids with known antibacterial activity exerted through bacterial cell membrane structural disruption, which contributes to a lower risk of developing resistance compared to antibiotics acting against specific targets on cells.
Researchers from Excision Biotherapeutics Inc. and affiliated organizations have reported the development of a novel CRISPR/Cas9-mediated genome editing therapy – EBT-104 – for the treatment of latent herpes simplex virus 1 (HSV-1) keratitis.
The Institute of Physical and Chemical Research, the National Institute of Infectious Diseases Japan and Shizuoka Prefectural University have discovered prodrugs of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors and reported to be useful for the treatment of viral infection.
Researchers from Thomas Jefferson University and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) have published findings from preclinical studies of LASSARAB, a new rabies-based Lassa virus (LASV) vaccine candidate.
Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
Immorna Biotherapeutics Inc. has received a grant from the Bill & Melinda Gates Foundation to support the clinical development of JCXH-108, a monovalent respiratory syncytial virus (RSV) vaccine based on Immorna’s proprietary mRNA and ready-to-use (RTU)-lipid nanoparticle (LNP) technologies.